Mammographic breast density (MBD) is a strong and highly heritable predictor of cancer risk biomarker for the disease. This study systematically assesses MBD as an endophenotype cancer—a quantitative trait that genetically correlated with disease risk. Using data from family-based kConFab Study 1994/1995 cross-sectional Busselton Health Study, participants were divided into three status groups—...

The World Health Organization states 'Early detection in order to improve breast cancer outcome and survival remains the cornerstone of breast cancer control' [WHO (World Health Organization) (2017) Breast cancer: prevention and control Available from: http://www.who.int/cancer/detection/breastcancer/en/]. Breast Density Matters UK is a non-profit breast cancer organization. The organization's ...

Breast density has been proven as an independent risk factor of breast cancer. Due to the limitation of two dimensional mammographic density, various alternative imaging modalities have been investigated to provide more quantitative measurement of breast density. Among these potential imaging tools, three dimensional (3D) magnetic resonance imaging (MRI) based density method is mostly studied. ...

Breast cancer screening is known to reduce breast cancer mortality. A high breast density may affect this reduction. We assessed the effect of screening on breast cancer mortality in women with dense and fatty breasts separately. Analyses were performed within the Nijmegen (Dutch) screening programme (1975-2008), which invites women (aged 50-74 years) biennially. Performance measures were deter...

BACKGROUND Several studies suggest antidepressant medications can increase prolactin levels. Some, but not all, studies suggest prolactin levels are positively associated with mammographic breast density, an established risk factor for breast cancer. METHODS We evaluated 29,284 women with two routine screening mammograms 9 to 28 months apart between 1996 to 2006 to examine whether antidepress...